Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two-dose heterologous vaccination regimens than single-dose regimens. Neutralising titres after heterologous prime-boost were at least comparable or higher than the titres measured after homologous prime boost vaccination with viral vectors. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1 + CD4 T cells, which is superior to the response induced in homologous vaccination regimens in mice. These results underpin the need for clinical trials to investigate the immunogenicity of heterologous regimens with alternate vaccine technologies. Heterologous vaccination regimens for COVID-19 could be useful for example if there is a shortage of one vaccine type. Here, Spencer et al . show that heterologous vaccination with a self-amplifying RNA vaccine and an adenoviral vectored vaccine performs at least as well as the homologous vaccinations in mice.
【저자키워드】 SARS-CoV-2, Adaptive immunity, Infectious diseases, Vaccines, 【초록키워드】 COVID-19, Efficacy, Vaccine, immune response, vaccination, immunogenicity, clinical trial, Cellular immune response, T cells, Antibody Response, Th1, clinical trials, RNA, Antibody responses, Cytotoxic T cells, mice, viral vectors, homologous, disease, ChAdOx1, RNA vaccine, Heterologous, boost, CD4 T cells, Cytotoxic T cell, Single-dose, heterologous prime-boost, regimen, titres, vectored vaccine, regimens, titre, heterologous vaccination regimens, example, demonstrated, comparable, heterologous vaccination regimen, Neutralising titre, 【제목키워드】 Vaccine, vaccination, RNA, COVID, regimen, robust, induce,